Toward Equitable Access to Cell and Gene Therapies: Rethinking Co-Payments

Why It Matters

Removing patient cost sharing for high‑value, curative therapies can close access gaps and align payer incentives with outcomes, accelerating adoption of life‑saving innovations.

Key Takeaways

• Co‑payments add thousands to patients’ out‑of‑pocket costs
• CAR‑T data reveal race and income access gaps
• Cost sharing offers little value‑signal for curative therapies
• Value‑based design can eliminate co‑payments and improve equity

Pulse Analysis

The rapid expansion of cell and gene therapies—ranging from CAR‑T for blood cancers to gene edits for rare genetic disorders—has reshaped the therapeutic landscape, but it has also introduced price points that dwarf traditional specialty drugs. Payers now grapple with budgeting for single‑administration treatments that can exceed $3 million, prompting a shift toward innovative payment models such as outcomes‑based contracts and amortized financing. Understanding these financial mechanisms is essential for insurers, providers, and investors seeking to sustain pipeline growth while managing budget impact.

Patient cost sharing, historically used to curb low‑value utilization, becomes counterproductive when applied to curative, physician‑administered therapies. Studies cited in the article demonstrate that even modest co‑payments deter eligible patients, amplifying existing disparities tied to race, income, and geography. For commercially insured and Medicare Advantage members, deductibles and coinsurance can push out‑of‑pocket spending into the thousands, prompting crowdfunding campaigns and, in extreme cases, medical bankruptcy. The evidence suggests that the traditional “skin‑in‑the‑game” rationale collapses when the clinical alternative is a potential cure rather than a discretionary medication.

A pragmatic solution lies in value‑based insurance design (VBID), which aligns patient cost exposure with therapeutic value. By eliminating co‑payments for high‑value, curative treatments, payers can remove financial barriers while still leveraging risk‑sharing mechanisms—such as outcome guarantees and long‑term registries—to protect against uncertain durability. This approach not only promotes equity but also encourages manufacturers to invest in robust real‑world evidence, fostering a virtuous cycle of innovation, affordability, and patient access. Policymakers and health‑system leaders should therefore codify VBID principles for cell and gene therapies to realize their full societal benefit.